SLC34A2 and central nervous system cancer: The life expectancy of patients with a high expression of SLC34A2 is significantly lower than that of patients with a lower expression of the gene in studies of brain (p < 0.043), ovarian (p < 0.0031), and pancreatic (p < 0.0015) cancer (cBioPortal, TCGA: Brain Lower Grade Glioma, n = 514, Glioblastoma multiforme, n = 592, Ovarian serous cystadenocarcinoma—n = 299, Pancreatic adenocarcinoma, n = 179, p < 0.05; Figure 3C–E).